beractant / Generic mfg. - LARVOL DELTA

Development and Validation of an HPLC-RI Method for the Simultaneous Determination of DPPC, Palmitic Acid, and Cholesterol in Bovine Pulmonary Surfactant. (PubMed, Biomed Chromatogr) - "The Iranian surfactant, Beraksurf, was used as the sample...Robustness testing revealed that minor variations in method parameters did not significantly impact results. This validated RP-HPLC-RID method provides a reliable and efficient approach for the analysis of key surfactant components, contributing to improved quality control in surfactant preparations and enhancing therapeutic strategies for managing RDS in infants."

Journal • Acute Respiratory Distress Syndrome • Respiratory Diseases

A Comparison of the Effect of Beractant (Beracsurf) and Proctant Alpha (Curosurf) in Neonatal Respiratory Distress: A Randomized Controlled Trial. (PubMed, Iran J Med Sci) - "The mortality rate in the Curosurf group was 24.3% (95% CI=10.5%-38.1%); while in the Beracsurf group, it was 10.6% (95% CI=1.8%-19.5%) (P=0.09). Beracsurf had comparable efficacy to Curosurf and could be considered a viable alternative.Trial Registration Number: IRCT20120126008827N3."

Clinical • Journal • Acute Respiratory Distress Syndrome • Respiratory Diseases

Comparing the Effect of Beractant (Beraksurf™) with That of Poractant Alfa (Curosurf®) on the Need for Intermittent Positive Pressure Ventilation in Neonatal Respiratory Distress Syndrome by Adopting a Semi-parametric Approach: Re-Analyzing Data of a Randomized Controlled Trial. (PubMed, BMC Pediatr) - "Fitting a semi-parametric model adjusted for the baseline covariates resulted in a marginal, unbiased, more efficient and interpretable estimation of BeraksurfTM versus Curosurf® effects. Although the crude model showed that BeraksurfTM was more effective than Curosurf®, the results of the efficient semi-parametric model with adjustment for the best subset of covariates revealed no statistically significant difference between the two drugs regarding their effects. We hope that the use of this method and its findings will contribute to a better understanding of covariate adjustment."

Clinical • Journal • Acute Respiratory Distress Syndrome • Respiratory Diseases

Comparison of Efficacy of Beractant (SURVANTA®) and Poractant Alfa (CUROSURF®) in Preterm Infants With Respiratory Distress Syndrome in Tawam Hospital, Al Ain, UAE: A Retrospective Study. (PubMed, Cureus) - "However, the rates of other outcomes, including significant patent ductus arteriosus (PDA), intraventricular hemorrhage (IVH), retinopathy of prematurity (ROP), periventricular leukomalacia (PVL), and necrotizing enterocolitis (NEC), were comparable in both treatment groups. Further randomized prospective studies are necessary to evaluate these types of surfactants and investigate their efficacy as well as both short- and long-term outcomes."

Journal • Retrospective data • Acute Respiratory Distress Syndrome • Bronchopulmonary Dysplasia • Gastrointestinal Disorder • Hematological Disorders • Pulmonary Disease • Respiratory Diseases • Retinal Disorders • Retinopathy of Prematurity

Comparative Biophysical Study of Clinical Surfactants using Constrained Drop Surfactometry. (PubMed, Am J Physiol Lung Cell Mol Physiol) - "At 10 mg/mL, Infasurf, Curosurf, and Survanta all demonstrated excellent dynamic surface activity, while Alveofact exhibited the poorest quasi-static and dynamic surface activity...Understanding the diverse biophysical behaviors of clinical surfactants provides crucial insights for precision and personalized design in treating RDS and other respiratory conditions. The findings from this study contribute valuable perspectives for development of more efficacious and fully synthetic surfactant preparations."

Journal • Acute Respiratory Distress Syndrome • Respiratory Diseases

Relaxatory Effects of Commercial Surfactants on Ductus Arteriosus Tone Reveals an Underlying Mechanism for Surfactant-Associated PDA (PAS 2024) - "Poractant alfa induced significant DA dilation under both oxygenated (118% reversal) and deoxygenated (22% change) conditions. In contrast, isolated DAs either had no response (BLES, calfactant) or were constricted by some surfactants (beractant (-17% change), SynSurf (-39% change)). Poractant, but not other surfactants, impaired O2-induced DA constriction."

Surfactant • Cardiovascular

Comparison of the Effectiveness of Beraksurf and Curosurf Exogenous Surfactants in the Treatment of Respiratory Distress Syndrome in Preterm Neonates: A Double-blind Randomized Study in the West of Iran. (PubMed, Curr Pediatr Rev) - "Based on the fact that Beracsurf and Curosurf surfactants did not show significant differences in the treatment outcomes of RDS in preterm neonates, it is suggested that the Iranianmade surfactant, Beracsurf, should be used for the treatment of these neonates due to its cost-effectiveness and availability compared to Curosurf."

Clinical • Acute Respiratory Distress Syndrome • Respiratory Diseases

Comparison of efficacy between beractant and poractant alfa in respiratory distress syndrome among preterm infants (28-33+6 weeks gestational age) using the less invasive surfactant administration (LISA) technique: A randomized controlled trial. (PubMed, J Perinatol) - "Beractant and poractant-alfa exhibit similar efficacy in LISA for preterm infants with RDS. Economic considerations, especially in LMICs, favour beractant. CLINICAL TRIAL REGISTATION: (CTRI/2023/03/050375)."

Journal • Acute Respiratory Distress Syndrome • Respiratory Diseases

Predictors of Extubation Failure in Very Low Birth Weight Infants at a Tertiary Care Hospital in Al Ain: A Retrospective Study. (PubMed, Cureus) - "The results of this research indicate that factors such as gestational age, birth weight, prenatal steroid use, delivery method, the quantity of Survanta® doses, PEEP, MAP, MAP (BP), and ID (+ve blood culture) were the primary determinants of unsuccessful extubation in VLBW babies at a tertiary healthcare facility in Al Ain. The predominant cause for needing reintubation was a FiO2 level above 50%, followed by Respiratory Acidosis. Additional ®®investigations are required to validate these findings and pinpoint other potential predictors of extubation failure within this demographic."

Journal • Retrospective data • Critical care • Infectious Disease • Metabolic Disorders

Comparison of the efficacy of two natural surfactants (BERAKSURF and BLES) in the treatment of respiratory distress syndrome among preterm neonates. (PubMed, BMC Pediatr) - "Despite advances in the use of exogenous surfactants for the treatment of neonatal respiratory distress syndrome; There are still some controversial topics in this field. The results obtained in the present study showed that the two types of surfactant (BERAKSURF and BLES) have similar efficacy for the treatment and short-term outcomes in preterm infants with respiratory distress syndrome. Therefore, due to the cost-effectiveness of BRAKSURF compared to BLES, We recommend choosing BERAKSURF in terms of treatment."

Journal • Acute Respiratory Distress Syndrome • Cardiovascular • Gastrointestinal Disorder • Heart Failure • Hematological Disorders • Infectious Disease • Respiratory Diseases • Septic Shock

Poractant alfa versus beractant in the treatment of preterm infants with respiratory distress syndrome (ASHP 2023) - No abstract available

Prematurity • Acute Respiratory Distress Syndrome • Respiratory Diseases

Evaluation of Treatment Outcomes Utilizing Beractant in Respiratory Distress Syndrome (ASHP 2023) - No abstract available

Clinical • Acute Respiratory Distress Syndrome • Respiratory Diseases

Gastric Aspirate Phosphatidylcholine Species in Preterm Neonates Receiving Aerosolized Surfactant. (PubMed, J Pediatr) - "PC molecular species in gastric aspirates of preterm neonates are potentially novel and precise biomarkers to assess lung maturity, aerosol delivery, and need for endotracheal intubation."

Journal • Acute Respiratory Distress Syndrome • Diabetes • Gestational Diabetes • Metabolic Disorders • Respiratory Diseases

Comparing the clinical and economic efficiency of four natural surfactants in treating infants with respiratory distress syndrome. (PubMed, PLoS One) - "So that some criteria were worse in Alveofact group infants than other groups; for example, in the comparison of the Alveofact group with the average of the total population, it was found that the survival rate at discharge was 57.14% versus 66.43%, and the rate of re-dosing was 1.63 versus 1.39. BLES (bovine lipid extract surfactant) was the best alternative for infants more than 32 weeks' gestation, whereas Survanta was identified as best option for infants with less than 32 weeks' gestation...This study advises the policy makers in the field of neonatal health to increase the market share of more effective surfactants based on this study and other similar studies. On the other hand, neonatal health care providers are also advised to prioritize the use of more effective surfactants if possible, depending on the clinical conditions and desired improvements."

Journal • Acute Respiratory Distress Syndrome • Respiratory Diseases

Comparison of Beractant Administration by thin Catheter vs Intubation-Surfactant-Extubation (INSURE) in Preterm Infants Less than 34 Weeks Gestational Age with Respiratory Distress Syndrome - A Single Centre Experience. (PubMed, J Neonatal Perinatal Med) - "Beractant administration by thin catheter reduces combined outcome of death/CLD."

Intubation • Journal • Acute Respiratory Distress Syndrome • Cardiovascular • Pulmonary Disease • Respiratory Diseases

Impact of PEEP on Surfactant Replacement Therapy in Acute Respiratory Distress Syndrome (ATS 2023) - "At peak injury (2 days post IT-LPS), mice were placed in 3 groups: a) No SRT, b) High dose SRT (IT Survanta™, 30 ug of PL/gm), c) Low dose SRT (7.5ug of PL/gm). At 4 hours after SRT dosing, mice were sedated (ketamine/xylazine), intratracheally annulated, connected to a Flexivent small animal ventilator (Scireq, Montreal CA) and paralyzed (pancuronium)... PEEP and SRT separately improve pathophysiology in ARDS. Benefits of SRT include compliance and hysteresis, which are most evident when levels of PEEP are lower and insufficient to achieve or maintain lung recruitment."

Surfactant • Acute Respiratory Distress Syndrome • Pulmonary Disease • Respiratory Diseases

Phase Transitions of the Pulmonary Surfactant Film at the Perfluorocarbon-Water Interface. (PubMed, Biophys J) - "Here we reported the first detailed biophysical study of phospholipid phase transitions in two animal-derived natural pulmonary surfactant films, Infasurf and Survanta, at the PFC-water interface using constrained drop surfactometry (CDS)...The pulmonary surfactant film at the PFC-water interface undergoes continuous phase transitions at surface pressures less than the equilibrium spreading pressure of 50 mN/m, and a monolayer-to-multilayer transition above this critical pressure. These results provided not only novel biophysical insight into the phase behavior of natural pulmonary surfactant at the oil-water interface but also translational implications into the further development of liquid ventilation and liquid breathing techniques."

Journal

Health Economic Studies of Surfactant Replacement Therapy in Neonates with Respiratory Distress Syndrome: A Systematic Literature Review. (PubMed, Pharmacoecon Open) - "There were no significant differences in NICU length of stay or NICU total costs between surfactants evaluated for treating neonates with RDS. However, early use of surfactant was found to be more clinically effective and cost-effective than late treatment. Treatment with poractant alfa was found to be cost-effective versus beractant and cost-saving compared with CPAP alone or beractant or CPAP in combination with calsurf. Limitations included the small number of studies, the geographic scope of the studies and the retrospective study design of the cost-effectiveness studies."

HEOR • Review • Acute Respiratory Distress Syndrome • Critical care • Respiratory Diseases

Impact of surfactants and other body fluids on in vitro activity of a novel β-lactamase inhibitor enmetazobactam in combination with cefepime against clinical isolates of Klebsiella pneumoniae. (PubMed, J Antibiot (Tokyo)) - "Therefore, the impact of surfactants, urine, and serum on the antibacterial activity of the novel β-lactam/β-lactamase inhibitor combination of cefepime-enmetazobactam (FPE) was determined...Minimal Inhibitory Concentration (MIC) determinations (all strains) and Time Kill Curves (TKC) (one clinical isolate) were determined for FPE and piperacillin-tazobactam (TZP) with and without surfactant formulations Survanta® (SUR; 1%v/v) and Curosurf® (CUR; 1 mg ml). Determination of daptomycin MIC against Staphylococcus aureus ATCC 29213 in the presence and absence of surfactants was used as a positive control...These results demonstrate that the antibacterial activity of FPE is unaffected in the presence of lung surfactant. Moreover, FPE was not impacted by media supplemented with urine or serum."

Combination therapy • Journal • Preclinical • Infectious Disease • Pneumonia • Respiratory Diseases

Use of budesonide associated with a pulmonary surfactant to prevent bronchopulmonary dysplasia in premature newborns - A systematic review. (PubMed, J Pediatr (Rio J)) - "Robust clinical studies, in a heterogeneous population, using porcine surfactant associated with budesonide, with administration by a minimally invasive technique are necessary for there to be a recommendation based on scientific evidence for its widespread use."

Clinical • Journal • Review • Acute Respiratory Distress Syndrome • Bronchopulmonary Dysplasia • Pulmonary Disease • Respiratory Diseases

Less Invasive Surfactant Administration: A Review of Current Evidence of Clinical Outcomes With Beractant. (PubMed, Cureus) - "This review provides a detailed assessment of the literature describing surfactant and LISA, with a focus on studies of beractant. Collectively, the available evidence supports the use of beractant with LISA based both on short-term and long-term outcomes relative to more invasive techniques and comparability of outcomes with small-volume surfactants and may be valuable in guiding clinical decision-making."

Clinical data • Journal • Review • Acute Respiratory Distress Syndrome • Bronchopulmonary Dysplasia • Pulmonary Disease • Respiratory Diseases

A Systematic Literature Review of the Economic Burden of Surfactant Use in the Treatment of Neonates with Respiratory Distress Syndrome (ISPOR-EU 2022) - "Despite no significant differences in terms of NICU total costs between surfactants evaluated for treating neonates with RDS, poractant alfa is cost-effective and associated with reduced overall treatment costs compared with beractant. Early poractant alfa administration is more cost-effective than late administration and cost-saving in early rescue with LISA versus CPAP alone."

HEOR • Review • Acute Respiratory Distress Syndrome • Critical care • Respiratory Diseases

Investigating the activity of pravibismane against bacterial isolates common in cystic fibrosis pulmonary infections (NACFC 2022) - "Pravibismane exhibited broad-spectrum activity against apanel of common CF pathogens, including nontuberculous mycobacteria.This work demonstrates that natural surfactant in the human lung does notadversely affect the antibacterial activity of pravibismane."

Cystic Fibrosis • Fibrosis • Genetic Disorders • Immunology • Infectious Disease • Nontuberculous Mycobacterial Disease • Pulmonary Disease • Respiratory Diseases • CAT

Comment on "Bilayer aggregate microstructure determines viscoelasticity of lung surfactant suspensions" by C. O. Ciutara and J. A. Zasadzinski, Soft Matter, 2021, 17, 5170-5182. (PubMed, Soft Matter) - "Ciutara and J. A. Zasadzinski, Soft Matter, 2021, 17, 5170-5182.) measured the rheological properties of Infasurf®, Survanta® and Curosurf®, three of the most used pulmonary surfactant substitutes...In contrast, we found that Curosurf® suspensions are viscous Newtonian or slightly shear-thinning fluids, with no evidence of yield stress. The purpose of this Comment is to discuss possible causes for the discrepancy between the two studies, and to suggest that for biological fluids such as surfactant substitutes, the microrheology technique of rotational magnetic spectroscopy (MRS) can provide valuable results."

Journal

WITHDRAWN: Cost-Utility Analysis of Calfactant Versus Poractant Alpha and/or Beractant in the Treatment of Respiratory Distress Syndrome (RDS) (ISPOR-EU 2022) - "Compared to poractant and beractant, calfactant was cost-effective in RDS preterm infants in the Iranian healthcare system."

HEOR • Acute Respiratory Distress Syndrome • Respiratory Diseases